{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/erectile-dysfunction/diagnosis/assessment/","result":{"pageContext":{"chapter":{"id":"bdb32096-c2e0-55ac-b935-a61204406095","slug":"assessment","fullItemName":"Assessment","depth":2,"htmlHeader":"<!-- begin field f93414f1-4f47-44d7-b462-acb07e2ec2e4 --><h2>How should I assess a man with erectile dysfunction?</h2><!-- end field f93414f1-4f47-44d7-b462-acb07e2ec2e4 -->","summary":"","htmlStringContent":"<!-- begin item 45815b91-3964-451b-b387-a321e4adad80 --><!-- begin field 969af717-4163-4114-bd6c-e5f3761ab330 --><p><strong>Take a detailed psychosexual, medical, and lifestyle history to determine the <a class=\"topic-reference internal-reference\" href=\"/topics/erectile-dysfunction/background-information/causes/\">cause</a> of the dysfunction (that is, organic, psychogenic, and/or drugs).</strong></p><ul><li>Where possible, the man's partner should be involved in the discussions.</li><li><strong>Psychosexual history should include questions on:</strong>  <ul><li>Sexual orientation.</li><li>Past and current sexual relationships.</li><li>Current emotional status.</li><li>Sexual function, including onset and duration of erectile problems; quality of erections (sexually-stimulated and morning erections); problems with sexual desire, arousal, ejaculation, and orgasm; and previous consultations and treatments.<ul><li><strong>Validated psychometric questionnaires,</strong> such as the <a href=\"https://www.baus.org.uk/_userfiles/pages/files/Patients/Leaflets/iief.pdf\" data-hyperlink-id=\"1be20f69-d7c7-460e-8ded-a993006d0b15\">International Index for Erectile Function</a> (IIEF) or its short version the <a href=\"https://www.baus.org.uk/_userfiles/pages/files/Patients/Leaflets/SHIM.pdf\" data-hyperlink-id=\"30b84fa2-4f34-47e9-839b-a993006d0b3a\">Sexual Health Inventory for Men</a> (SHIM), are available and can help to assess the different sexual function domains (such as sexual desire, erectile function, orgasmic function, intercourse, and overall satisfaction) as well as the potential impact of a specific treatment.</li></ul></li><li>Issues with sexual aversion or pain, or issues for his partner (including menopause or vaginal pain).  </li></ul></li><li><strong>Medical history should include questions on:</strong><ul><li>Current and past medical, surgical, and psychiatric history.</li><li>Psychological (or emotional) factors, such as anxiety and depression. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> and <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> for more information.</li><li>Other symptoms experienced, including symptoms of possible hypogonadism (including decreased energy, libido, fatigue, and cognitive impairment) and lower urinary tract symptoms (LUTS). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/luts-in-men/\">LUTS in men</a> for more information.</li><li>Medication(s) for comorbidities. </li></ul></li><li><strong>Lifestyle history should include questions on:</strong><ul><li>The use of alcohol, tobacco, and illicit drugs (including cannabis and cocaine).</li><li>Level of exercise tolerance, to assess the <a class=\"topic-reference internal-reference\" href=\"/topics/erectile-dysfunction/diagnosis/assessment/#cardiac-risk-stratification\">cardiac risk of sexual activity</a>. </li></ul></li><li><strong>History suggesting an organic cause for erectile dysfunction include</strong> gradual onset of symptoms, lack of tumescence, normal libido, and presence of <a class=\"topic-reference internal-reference\" href=\"/topics/erectile-dysfunction/background-information/causes/\">risk factors</a> (such as the use of drug associated with erectile dysfunction [for example diuretics], smoking, and high alcohol consumption).</li><li><strong>History suggesting a psychogenic cause for erectile dysfunction include</strong> sudden onset of symptoms, decreased libido, good quality spontaneous or self-stimulated erections, major life events, problems or changes in a relationship, and previous psychological problems.</li></ul><p><strong>Perform a focused physical examination (as directed by history) to identify any genitourinary, endocrine, vascular, or neurological cause of erectile dysfuction. </strong></p><ul><li>Measure blood pressure, heart rate, waist circumference, and weight (and body mass index [BMI]), if they have not been assessed in the previous 3–6 months. </li><li>Examine the genitalia (this is essential if there is a history of rapid onset of pain, deviation of the erection, and/or past or present urological symptoms). Examination may reveal:<ul><li>Pre-malignant or malignant genital lesions.</li><li>Prostatic enlargement or irregularity/nodularity.</li><li>Signs of hypogonadism, such as small testes and alterations in secondary sexual characteristics.</li><li>Penile deformities, such as Peyronie's disease (an inflammatory condition that can result in deformity and bending of the penis).  </li></ul></li><li>Check for gynaecomastia and reduced body hair to assess the degree of androgenisation.</li><li>A digital rectal examination (DRE) is recommended:<ul><li>If there are symptoms of an enlarged prostate, including obstructive urinary symptoms (such as a weak and intermittent urinary stream). Rarely, the enlarged prostate obstructs the flow of ejaculate causing prolonged and intermittent ejaculation.</li><li>In men with a history of prostate cancer.</li><li>In men aged over 50 years.</li></ul></li></ul><p><strong>Arrange appropriate investigations to identify any reversible/modifiable <a class=\"topic-reference internal-reference\" href=\"/topics/erectile-dysfunction/background-information/causes/\">risk factor</a> of erectile dysfunction.</strong></p><ul><li><strong>In all men:</strong><ul><li>Measure HbA1c or fasting blood glucose and lipid profile (if they have not recently been assessed).<ul><li>Diabetes is usually diagnosed by an HbA1c of 48 mmol/mol (6.5%) or more, or a fasting plasma glucose level of 7.0 mmol/L or greater (if the use of HbA1c is inappropriate). HbA1c or fasting blood glucose can also be used to assess glycaemic control in men with confirmed diabetes. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a> and <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a> for more information.</li><li>A lipid profile as well as the man's blood pressure and BMI can be used to calculate the 10-year cardiovascular risk. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> for more information.</li></ul></li><li>Measure a morning sample of total testosterone. If indicated, measure bioavailable or calculated-free testosterone to confirm total testosterone measurements. If the free testosterone is low or borderline:<ul><li>Repeat the testosterone measurement, and measure follicle-stimulating hormone, luteinizing hormone, and prolactin levels.</li><li>Consider referral to endocrinology if these are abnormal.</li></ul></li></ul></li><li><strong>In men with pre-existing cardiovascular disease, </strong>assess the <a class=\"topic-reference internal-reference\" href=\"/topics/erectile-dysfunction/diagnosis/assessment/#cardiac-risk-stratification\">cardiovascular risk of sexual activity</a>.</li><li><strong>Arrange other investigations as directed by the person's history and examination, </strong>such as prostate-specific antigen (PSA) if the DRE result is abnormal and the man is aged over 50 years (and is requesting screening or has risk factors for prostate cancer) or if testosterone replacement is being considered.</li></ul><!-- end field 969af717-4163-4114-bd6c-e5f3761ab330 --><!-- end item 45815b91-3964-451b-b387-a321e4adad80 -->","topic":{"id":"5bdc98b8-cec1-551c-a1ea-d279c1d4a789","topicId":"a255a0a6-1216-4961-a8d2-0841d9ddf8fe","topicName":"Erectile dysfunction","slug":"erectile-dysfunction","lastRevised":"Last revised in July 2020","chapters":[{"id":"60de3c56-e8f8-5ed1-af6c-079fbfc5297a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1390eb84-15de-5511-a888-7aa10c5f380e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6f0e3524-4bd9-524b-b0c7-5df8463a2632","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6f8d7396-341b-5cdb-9ab7-11d371aecf1b","slug":"changes","fullItemName":"Changes"},{"id":"7273623f-46a6-55a9-b20f-3174d857bb0b","slug":"update","fullItemName":"Update"}]},{"id":"954f3dd9-902d-5807-89cb-b68e9a352975","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4dbc024b-ad9c-5c73-975f-44d47f56c8db","slug":"goals","fullItemName":"Goals"},{"id":"3c8ab157-63cf-5e79-95c8-8d533751d80b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c87478c5-0e05-5e5e-aff4-92c6bd965c7e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7aad46cb-3cd1-586a-9eb7-5b41fb304896","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"792aba04-631e-555e-8bf8-2c58ec675d8d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19da5bcc-2817-5766-9335-d7974d14f3c4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9a1a9a32-e4af-5cb5-83a9-c382b1ee5d40","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ecd0b9da-d509-587d-9c32-4e2828d198af","slug":"definition","fullItemName":"Definition"},{"id":"a0eac8e3-a0a4-5026-870e-24f5a5597b63","slug":"causes","fullItemName":"Causes"},{"id":"1e4fb7fb-80f2-58a9-9f0a-cd2a06bd58f5","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8f1a78ac-cb2e-5627-aaf2-9eddf7d19863","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fd7eccbd-c104-54ec-aa7e-7b5d8c806ded","slug":"prognosis","fullItemName":"Prognosis"},{"id":"3dbe567c-f646-542c-a649-49c5e0a2e1d8","slug":"complications","fullItemName":"Complications"}]},{"id":"a7b9bdc4-1390-5184-aa4d-a331be735168","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"bdb32096-c2e0-55ac-b935-a61204406095","slug":"assessment","fullItemName":"Assessment"}]},{"id":"7b089806-f4ac-58ac-a788-629e509b4868","fullItemName":"Management","slug":"management","subChapters":[{"id":"09f9cf76-1bbb-5d37-8bf8-9ed3fd4a9b64","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"92e38517-29a0-5e5f-8e17-2959aa09e71a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0d5ad6d5-d065-5eb5-99c8-b654497d8d19","slug":"phosphodiesterase-5-pde-5-inhibitors","fullItemName":"Phosphodiesterase-5 (PDE-5) inhibitors"}]},{"id":"f021401a-d917-5e2c-b234-816a1108de92","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c0f733e9-9f61-5807-8fce-90a6aba44893","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ab85ccb2-6023-521d-b0ed-2cf9647aff63","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"536d66ad-375a-52d4-a2ee-1dfc1ec8a13e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d1ea3b0d-cce2-5191-82e1-3149d32c0296","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c69a15f7-87a5-5513-b5d1-b21a85dd1561","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1d54146b-d6e9-54f2-885a-74200666af7c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"04d092eb-cbf9-5bce-9d0d-65e9e5d6ba1b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a7b9bdc4-1390-5184-aa4d-a331be735168","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"ecfc4085-10ff-5482-8341-cc100f271790","slug":"cardiac-risk-stratification","fullItemName":"Cardiac risk stratification","depth":3,"htmlHeader":"<!-- begin field 9eb73861-25a7-4212-9464-a82900f12221 --><h3>Cardiac risk stratification</h3><!-- end field 9eb73861-25a7-4212-9464-a82900f12221 -->","summary":null,"htmlStringContent":"<!-- begin item ff5e8d9c-2818-4795-8aa2-a82900f11890 --><!-- begin field a426f4ec-612c-4592-bac5-a82900f12221 --><p><strong>Men with erectile dysfunction can be stratified into three cardiovascular risk categories: low risk, intermediate or indeterminate risk, or high risk </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Nehra et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">European Association of Urology, 2017</a>]<strong>.</strong></p><ul><li><strong>Low risk</strong> includes men who do not have any significant cardiac risk associated with sexual activity.<ul><li>This includes men:<ul><li>Who are asymptomatic and have less than 3 risk factors for coronary artery disease (CAD, excluding gender).</li><li>With controlled hypertension, mild valvular disease, and left ventricular dysfunction/congestive heart failure (LVD/CHF, New York Heart Association [NYHA] class I and II).</li><li>Who have had successful coronary revascularisation (for example via coronary artery bypass grafting, stenting, or angioplasty). </li></ul></li><li>Low-risk is typically implied by the ability to perform exercise of modest intensity without symptoms. </li><li>Men at low risk can be <a class=\"topic-reference internal-reference\" href=\"/topics/erectile-dysfunction/management/management/\">managed</a> in primary care and do not need cardiac testing or evaluation before the initiation or resumption of sexual activity. </li></ul></li><li><strong>Intermediate or indeterminate risk</strong> includes men with an uncertain cardiac condition. <ul><li>This includes men with:<ul><li>Three or more risk factors for CAD (excluding gender).</li><li>Mild or moderate stable angina.</li><li>Past myocardial infarction (MI, within the last 2–8 weeks) without intervention awaiting exercise electrocardiography.</li><li>LVD/CHF (NYHA class III).</li><li>Noncardiac sequelae of atherosclerotic disease (for example peripheral vascular disease and a history of stroke or transient ischemic attack). </li></ul></li><li>Specialist testing or evaluation is recommended before the resumption of sexual activity in this group of men. Based on the results of testing, men at intermediate or indeterminate risk may be moved to either the high-risk group or low-risk group. </li></ul></li><li><strong>High risk</strong> includes men who have a cardiac condition that is sufficiently severe and/or unstable for sexual activity to carry a significant risk. <ul><li>This includes men with:<ul><li>Unstable or refractory angina.</li><li>Uncontrolled hypertension.</li><li>LVD/CHF (NYHA class IV).</li><li>Recent MI without intervention (within the last 2 weeks).</li><li>High-risk arrhythmia (exercise-induced ventricular tachycardia, implanted internal cardioverter defibrillator with frequent shocks, and poorly controlled atrial fibrillation).</li><li>Obstructive hypertrophic cardiomyopathy with severe symptoms.</li><li>Moderate to severe valve disease (particularly aortic stenosis).</li></ul></li><li>Most of these men have moderate-to-severe symptomatic heart disease.</li><li>Men at high risk should be referred for cardiac assessment and treatment. Sexual activity should be stopped until the cardiac condition has been stabilized by treatment, or a decision made by the cardiologist that it is safe to resume sexual activity.</li></ul></li></ul><!-- end field a426f4ec-612c-4592-bac5-a82900f12221 --><!-- end item ff5e8d9c-2818-4795-8aa2-a82900f11890 -->","subChapters":[]},{"id":"b27ef7ad-702b-50ec-88ac-68521ccf321d","slug":"basis-for-recommendation-caa","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 92575338-2055-4ca6-816a-0edbca722417 --><h3>Basis for recommendation</h3><!-- end field 92575338-2055-4ca6-816a-0edbca722417 -->","summary":null,"htmlStringContent":"<!-- begin item caa8145c-c482-4c8e-9b6f-66a67aa298a2 --><!-- begin field 48b987a4-f90b-4c9b-b771-55b3aedf8342 --><p>These recommendations are based largely on the British Society for Sexual Medicine (BSSM) <em>Guidelines on the management of erectile dysfunction</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BSSM, 2017</a>], the European Association of Urology (EAU) G<em>uidelines on male sexual dysfunction </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">European Association of Urology, 2017</a>], and <em>The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Nehra et al, 2012</a>], and are consistent with recommendations in several systematic reviews [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Binmoammar et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Kouidrat et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Nguyen, 2017</a>]  and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Muneer, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Rajendran, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Papagiannopoulos, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Randrup, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BMJ, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Raheem et al, 2017</a>] on erectile dysfunction. </p><h4>History, examination, and investigation</h4><ul><li>Erectile dysfunction is a complicated disorder with several possible organic and psychogenic causes and risk factors. A detailed history, examination, and investigation is important to ascertain these causes and risk factors in order to provide optimal management (treatment or referral) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BSSM, 2017</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Muneer, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">European Association of Urology, 2017</a>].</li><li>The EAU guideline states that although physical examination and laboratory investigation of most men with erectile dysfunction may not reveal the exact diagnosis, these present opportunities to identify serious comorbid conditions that should not be missed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">European Association of Urology, 2017</a>].</li><li><strong>History</strong><ul><li>The recommendation to establish a relaxed atmosphere during history taking is based on the EAU guideline, which states that doing this will make it easier to ask questions about erectile function and other aspects of the sexual history and to explain the diagnosis and therapeutic approach to the man [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">European Association of Urology, 2017</a>].</li><li>The EAU also advises that, where possible, the man's partner should be part of the process, as decisions affect both partners. However, this may be challenging; bearing in mind the sensitive nature of erectile dysfunction, men may be reluctant to involve their partners.</li><li>The information on history suggesting a psychogenic and organic cause for erectile dysfunction is based on expert opinion in a systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Nguyen, 2017</a>] and in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Muneer, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Papagiannopoulos, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BMJ, 2017</a>].</li></ul></li><li><strong>Physical examination</strong><ul><li>A physical examination is essential to identify underlying medical conditions that may be associated with erectile dysfunction and to rule out some physical disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BSSM, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">European Association of Urology, 2017</a>].</li></ul></li><li><strong>Investigations</strong><ul><li>Investigations are required to identify and treat any reversible/modifiable risk factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">European Association of Urology, 2017</a>].</li><li>Glucose-lipid profile is recommended for all men with new presentations of erectile dysfunction, due to the strong association of erectile dysfunction with cardiovascular disease (CVD) and diabetes. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/erectile-dysfunction/background-information/causes/\">Causes and risk factors</a> for more information.<ul><li>The BSSM advises that erectile dysfunction in an otherwise asymptomatic man may be a marker for underlying coronary artery disease; therefore, all men with unexplained erectile dysfunction should have a thorough evaluation to identify risk factors for coronary heart disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BSSM, 2017</a>].</li><li>Expert opinion in a review article is that men presenting with erectile dysfunction should be screened for underlying diabetes, CVD, and hypogonadism, as this will provide an opportunity to intervene (including lifestyle modifications) and improve both the erectile dysfunction and cardiovascular health [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Rajendran, 2014</a>].</li><li>The National Institute for Health and Care Excellence guidelines on <em>Type 1 diabetes in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">NICE, 2015a</a>] and <em>Type 2 diabetes in adults: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">NICE, 2015b</a>] recommends that men with diabetes should be offered the opportunity to discuss erectile dysfunction as part of their annual review. </li></ul></li><li>CKS recommends universal measurement of testosterone levels as recommended by the BSSM [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BSSM, 2017</a>], the EAU [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">European Association of Urology, 2017</a>], and the 3rd Princeton Consensus [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Nehra et al, 2012</a>].<ul><li>The consensus opinion of the BSSM is that testosterone screening is pragmatic in light of the fact that testosterone deficiency is reversible and can have a negative impact on phosphodiesterase-5 inhibitor efficacy. They advise that men with consistently low total serum testosterone levels (less than 12 nmol/l) may benefit from up to a 6 months trial of testosterone replacement therapy for erectile dysfunction [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BSSM, 2017</a>].</li></ul></li><li>The recommendations on when to arrange a prostate-specific antigen test is based on expert opinion in the BSSM guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BSSM, 2017</a>] and in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Muneer, 2014</a>].</li></ul></li></ul><h4>Cardiac risk stratification</h4><ul><li>This information is taken from the BSSM guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">BSSM, 2017</a>] and the EAU guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">European Association of Urology, 2017</a>] and was adapted from the third Princeton Consensus (which is is dedicated to optimising sexual function and preserving cardiovascular health) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Nehra et al, 2012</a>].<ul><li>The recommendations in the third Princeton Consensus are similar to those developed during the first and second Princeton Consensus Conferences, with the following changes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/erectile-dysfunction/references/\">Nehra et al, 2012</a>]:<ul><li>The current recommendations classify men with left ventricular dysfunction/congestive heart failure (New York Heart Association [NYHA] class II) as low risk rather than intermediate risk as in previous recommendations — this group of men are still classified as intermediate risk in the BSSM guideline.</li><li>Men with LVD/CHF (NYHA class III) have been moved from high to intermediate risk — this group of men are still classified as high risk in the BSSM guideline.</li><li>Men with mild, stable angina have been reclassified as intermediate risk rather than low risk as in previous recommendations — this group of men are still classified as low risk in the BSSM and EAU guidelines.</li><li>Men with past myocardial infarction (MI, more than 6–8 weeks) have been reclassified as intermediate risk rather than low risk as in previous recommendations — the EAU guideline has also classified men with uncomplicated previous MI as low risk.</li></ul></li><li>The EAU advises that it is also possible for the clinician to estimate the risk of sexual activity in most people from their level of exercise tolerance, which can be determined when taking the person’s history.</li></ul></li></ul><!-- end field 48b987a4-f90b-4c9b-b771-55b3aedf8342 --><!-- end item caa8145c-c482-4c8e-9b6f-66a67aa298a2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}